;PMID: 1638401
;source_file_861.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..187] = [t:44..187]
;2)section:[e:191..250] = [t:191..249]
;3)section:[e:254..336] = [t:254..336]
;4)sentence:[e:340..445] = [t:340..445]
;5)sentence:[e:446..577] = [t:446..577]
;6)sentence:[e:578..681] = [t:578..681]
;7)sentence:[e:682..997] = [t:682..997]
;8)sentence:[e:998..1160] = [t:998..1160]
;9)sentence:[e:1161..1477] = [t:1161..1477]
;10)sentence:[e:1478..1593] = [t:1478..1593]
;11)sentence:[e:1594..1861] = [t:1594..1861]
;12)sentence:[e:1862..2085] = [t:1862..2085]
;13)sentence:[e:2086..2292] = [t:2086..2292]
;14)section:[e:2296..2340] = [t:2296..2339]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:191..250][t:191..249]
;ERROR_Section end mismatch[e:2296..2340][t:2296..2339]
;Token/POS Errors
;ERROR_Token in entity file but not tree[249..250] .
;ERROR_Token in entity file but not tree[2339..2340] ]

;section 0 Span:0..38
;Brain Res. 1992 Mar 6;574(1-2):280-90.
(SEC
  (FRAG (NNP:[0..5] Brain) (NNP:[6..9] Res) (.:[9..10] .) (CD:[11..15] 1992)
        (NNP:[16..19] Mar) (CD:[20..21] 6) (::[21..22] ;) (CD:[22..25] 574)
        (-LRB-:[25..26] -LRB-) (CD:[26..27] 1) (HYPH:[27..28] -) (CD:[28..29] 2)
        (-RRB-:[29..30] -RRB-) (::[30..31] :) (CD:[31..34] 280) (::[34..35] -)
        (CD:[35..37] 90) (.:[37..38] .)))

;sentence 1 Span:44..187
;Neuroanatomical specificity in the autoregulation of aromatase-immunoreactive
; neurons by androgens and estrogens: an immunocytochemical study.
;[97..106]:cyp450:"aromatase"
;[134..143]:substance:"androgens"
;[148..157]:substance:"estrogens"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[44..59] Neuroanatomical) (NN:[60..71] specificity))
      (PP (IN:[72..74] in)
        (NP
          (NP (DT:[75..78] the) (NN:[79..93] autoregulation))
          (PP (IN:[94..96] of)
            (NP
              (ADJP (NN:[97..106] aromatase) (HYPH:[106..107] -)
                    (JJ:[107..121] immunoreactive))
              (NNS:[123..130] neurons)))))
      (PP (IN:[131..133] by)
        (NP (NNS:[134..143] androgens) (CC:[144..147] and)
            (NNS:[148..157] estrogens))))
    (::[157..158] :)
    (NP (DT:[159..161] an) (JJ:[162..180] immunocytochemical)
        (NN:[181..186] study))
    (.:[186..187] .)))

;section 2 Span:191..249
;Balthazart J, Foidart A, Surlemont C, Harada N, Naftolin F
(SEC
  (FRAG (NNP:[191..201] Balthazart) (NNP:[202..203] J) (,:[203..204] ,)
        (NNP:[205..212] Foidart) (NNP:[213..214] A) (,:[214..215] ,)
        (NNP:[216..225] Surlemont) (NNP:[226..227] C) (,:[227..228] ,)
        (NNP:[229..235] Harada) (NNP:[236..237] N) (,:[237..238] ,)
        (NNP:[239..247] Naftolin) (NNP:[248..249] F)))

(ORPH .)

;section 3 Span:254..336
;Laboratory of General and Comparative Biochemistry, University of Liege, 
;Belgium.
(SEC
  (FRAG (NN:[254..264] Laboratory) (IN:[265..267] of) (NNP:[268..275] General)
        (CC:[276..279] and) (NNP:[280..291] Comparative)
        (NNP:[292..304] Biochemistry) (,:[304..305] ,)
        (NNP:[306..316] University) (IN:[317..319] of) (NNP:[320..325] Liege)
        (,:[325..326] ,) (NNP:[328..335] Belgium) (.:[335..336] .)))
;ERROR_Orphan Text from Tree File[249..254] .

;sentence 4 Span:340..445
;Testosterone (T) increases brain aromatase activity (AA) in quail and other 
;avian and mammalian species.
;[340..352]:substance:"Testosterone"
;[354..355]:substance:"T"
;[373..391]:cyp450:"aromatase activity"
;[393..395]:cyp450:"AA"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[340..352] Testosterone))
      (NP (-LRB-:[353..354] -LRB-) (NN:[354..355] T) (-RRB-:[355..356] -RRB-)))
    (VP (VBZ:[357..366] increases)
      (NP
        (NP (NN:[367..372] brain)
           (NN:[373..382] aromatase) (NN:[383..391] activity))
        (NP (-LRB-:[392..393] -LRB-) (NN:[393..395] AA) (-RRB-:[395..396] -RRB-)))
      (PP-LOC (IN:[397..399] in)
        (NP
          (NP (NN:[400..405] quail))
          (CC:[406..409] and)
          (NP
            (NP (JJ:[410..415] other) (JJ:[417..422] avian)
              (NML-1 (-NONE-:[422..422] *P*)))
            (CC:[423..426] and)
            (NP (JJ:[427..436] mammalian)
              (NML-1 (NNS:[437..444] species)))))))
    (.:[444..445] .)))

;sentence 5 Span:446..577
;It was shown both in quail and in rat that this  enzymatic induction results
;from a synergistic action of androgens and  estrogens.
;[552..561]:substance:"androgens"
;[567..576]:substance:"estrogens"
(SENT
  (S
    (NP-SBJ-2
      (NP (PRP:[446..448] It))
      (SBAR-1 (-NONE-:[448..448] *EXP*)))
    (VP (VBD:[449..452] was)
      (VP (VBN:[453..458] shown)
        (NP-2 (-NONE-:[458..458] *))
        (PP-LOC (CC:[459..463] both)
          (PP (IN:[464..466] in)
            (NP (NN:[467..472] quail)))
          (CC:[473..476] and)
          (PP (IN:[477..479] in)
            (NP (NN:[480..483] rat))))
        (SBAR-1 (IN:[484..488] that)
          (S
            (NP-SBJ (DT:[489..493] this) (JJ:[495..504] enzymatic)
                    (NN:[505..514] induction))
            (VP (VBZ:[515..522] results)
              (PP-CLR (IN:[523..527] from)
                (NP
                  (NP (DT:[528..529] a) (JJ:[530..541] synergistic)
                      (NN:[542..548] action))
                  (PP (IN:[549..551] of)
                    (NP (NNS:[552..561] androgens) (CC:[562..565] and)
                        (NNS:[567..576] estrogens))))))))))
    (.:[576..577] .)))

;sentence 6 Span:578..681
;These studies provide little information on possible anatomical or  cellular
;specificity of the effect.
(SENT
  (S
    (NP-SBJ (DT:[578..583] These) (NNS:[584..591] studies))
    (VP (VBP:[592..599] provide)
      (NP
        (NP (JJ:[600..606] little) (NN:[607..618] information))
        (PP (IN:[619..621] on)
          (NP
            (NP
              (NP
                (ADJP-2 (JJ:[622..630] possible))
                (JJ:[631..641] anatomical)
                (NML-1 (-NONE-:[641..641] *P*)))
              (CC:[642..644] or)
              (NP
                (ADJP-2 (-NONE-:[644..644] *P*))
                (JJ:[646..654] cellular)
                (NML-1 (NN:[655..666] specificity))))
            (PP (IN:[667..669] of)
              (NP (DT:[670..673] the) (NN:[674..680] effect)))))))
    (.:[680..681] .)))

;sentence 7 Span:682..997
;Using a polyclonal antiserum against human  placental aromatase, we have
;previously identified aromatase-immunoreactive  (ARO-ir) neurons in the quail
;brain and demonstrated that T increases the number  of ARO-ir cells in the
;quail preoptic area (POA) supporting previous evidence  that T increases AA
;in the brain.
;[736..745]:cyp450:"aromatase"
;[777..786]:cyp450:"aromatase"
;[861..862]:substance:"T"
;[969..970]:substance:"T"
;[981..983]:cyp450:"AA"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[682..682] *))
      (VP (VBG:[682..687] Using)
        (NP
          (NP (DT:[688..689] a) (JJ:[690..700] polyclonal)
              (NN:[701..710] antiserum))
          (PP (IN:[711..718] against)
            (NP (JJ:[719..724] human) (JJ:[726..735] placental)
                (NN:[736..745] aromatase))))))
    (,:[745..746] ,)
    (NP-SBJ (PRP:[747..749] we))
    (VP (VBP:[750..754] have)
      (VP
        (ADVP-TMP (RB:[755..765] previously))
        (VP
          (VP (VBN:[766..776] identified)
            (NP
              (ADJP
                (ADJP (NN:[777..786] aromatase) (HYPH:[786..787] -)
                      (JJ:[787..801] immunoreactive))
                (ADJP (-LRB-:[803..804] -LRB-) (NN:[804..810] ARO-ir)
                      (-RRB-:[810..811] -RRB-)))
              (VBZ:[812..819] neurons))
            (PP-LOC (IN:[820..822] in)
              (NP (DT:[823..826] the) (NN:[827..832] quail)
                  (NN:[833..838] brain))))
          (CC:[839..842] and)
          (VP (VBN:[843..855] demonstrated)
            (SBAR (IN:[856..860] that)
              (S
                (NP-SBJ (NN:[861..862] T))
                (VP (VBZ:[863..872] increases)
                  (NP
                    (NP (DT:[873..876] the) (NN:[877..883] number))
                    (PP (IN:[885..887] of)
                      (NP (NN:[888..894] ARO-ir) (NNS:[895..900] cells))))
                  (PP-LOC (IN:[901..903] in)
                    (NP (DT:[904..907] the) (NN:[908..913] quail)
                      (NML
                        (NML (JJ:[914..922] preoptic) (NN:[923..927] area))
                        (NML (-LRB-:[928..929] -LRB-) (NN:[929..932] POA)
                             (-RRB-:[932..933] -RRB-)))))
                  (VP (VBG:[934..944] supporting)
                    (NP
                      (NP (JJ:[945..953] previous) (NN:[954..962] evidence))
                      (SBAR (IN:[964..968] that)
                        (S
                          (NP-SBJ (NN:[969..970] T))
                          (VP (VBZ:[971..980] increases)
                            (NP (NN:[981..983] AA))
                            (PP-LOC (IN:[984..986] in)
                              (NP (DT:[987..990] the) (NN:[991..996] brain)))))))))))))))
    (.:[996..997] .)))

;sentence 8 Span:998..1160
;However, which T metabolites are involved, the  actual mechanism of
;regulation and the possibility of anatomical specificity for  these effects
;are not yet clear.
;[1013..1026]:substance:"T metabolites"
(SENT
  (S
    (ADVP (RB:[998..1005] However))
    (,:[1005..1006] ,)
    (SBAR-ADV
      (WHNP-2 (WDT:[1007..1012] which)
         (NN:[1013..1014] T) (NNS:[1015..1026] metabolites))
      (S
        (NP-SBJ-2 (-NONE-:[1026..1026] *T*))
        (VP (VBP:[1027..1030] are)
          (VP (VBN:[1031..1039] involved))
          (NP-2 (-NONE-:[1039..1039] *)))))
    (,:[1039..1040] ,)
    (NP-SBJ
      (NP
        (NP (DT:[1041..1044] the) (JJ:[1046..1052] actual)
            (NN:[1053..1062] mechanism))
        (PP (IN:[1063..1065] of)
          (NP (NN:[1066..1076] regulation))))
      (CC:[1077..1080] and)
      (NP
        (NP (DT:[1081..1084] the) (NN:[1085..1096] possibility))
        (PP (IN:[1097..1099] of)
          (NP (JJ:[1100..1110] anatomical) (NN:[1111..1122] specificity)))
        (PP (IN:[1123..1126] for)
          (NP (DT:[1128..1133] these) (NNS:[1134..1141] effects)))))
    (VP (VBP:[1142..1145] are)
      (ADVP-TMP (RB:[1146..1149] not) (RB:[1150..1153] yet))
      (ADJP-PRD (JJ:[1154..1159] clear)))
    (.:[1159..1160] .)))

;sentence 9 Span:1161..1477
;In the present study, we disassociated the  effects of androgens and
;estrogens in aromatase induction by comparing ARO-ir  neurons of quail
;treated with T alone or T in the presence of a potent aromatase  inhibitor
;(R76713), which has been shown to depress AA levels and to suppress 
;T-activated copulatory behavior.
;[1216..1225]:substance:"androgens"
;[1230..1239]:substance:"estrogens"
;[1243..1252]:cyp450:"aromatase"
;[1314..1315]:substance:"T"
;[1325..1326]:substance:"T"
;[1355..1364]:cyp450:"aromatase"
;[1366..1375]:substance:"inhibitor"
;[1377..1383]:substance:"R76713"
;[1418..1420]:cyp450:"AA"
;[1445..1446]:substance:"T"
(SENT
  (S
    (PP-LOC (IN:[1161..1163] In)
      (NP (DT:[1164..1167] the) (JJ:[1168..1175] present)
          (NN:[1176..1181] study)))
    (,:[1181..1182] ,)
    (NP-SBJ (PRP:[1183..1185] we))
    (VP (VBD:[1186..1199] disassociated)
      (NP
        (NP (DT:[1200..1203] the) (NNS:[1205..1212] effects))
        (PP (IN:[1213..1215] of)
          (NP (NNS:[1216..1225] androgens) (CC:[1226..1229] and)
              (NNS:[1230..1239] estrogens)))
        (PP (IN:[1240..1242] in)
          (NP (JJ:[1243..1252] aromatase) (NN:[1253..1262] induction))))
      (PP-MNR (IN:[1263..1265] by)
        (S-NOM
          (NP-SBJ (-NONE-:[1265..1265] *))
          (VP (VBG:[1266..1275] comparing)
            (NP
              (NP
                (NP (NN:[1276..1282] ARO-ir) (NNS:[1284..1291] neurons))
                (PP (IN:[1292..1294] of)
                  (NP (NN:[1295..1300] quail))))
              (VP (VBN:[1301..1308] treated)
                (PP-CLR (IN:[1309..1313] with)
                  (NP
                    (NP (NN:[1314..1315] T) (RB:[1316..1321] alone))
                    (CC:[1322..1324] or)
                    (NP
                      (NP (NN:[1325..1326] T))
                      (PP (IN:[1327..1329] in)
                        (NP
                          (NP (DT:[1330..1333] the) (NN:[1334..1342] presence))
                          (PP (IN:[1343..1345] of)
                            (NP
                              (NP
                                (NP (DT:[1346..1347] a) (JJ:[1348..1354] potent)
                                    (NN:[1355..1364] aromatase)
                                    (NN:[1366..1375] inhibitor))
                                (NP (-LRB-:[1376..1377] -LRB-)
                                    (NN:[1377..1383] R76713)
                                    (-RRB-:[1383..1384] -RRB-)))
                              (,:[1384..1385] ,)
                              (SBAR
                                (WHNP-1 (WDT:[1386..1391] which))
                                (S
                                  (NP-SBJ-1 (-NONE-:[1391..1391] *T*))
                                  (VP (VBZ:[1392..1395] has)
                                    (VP (VBN:[1396..1400] been)
                                      (VP (VBN:[1401..1406] shown)
                                        (NP-1 (-NONE-:[1406..1406] *))
                                        (VP
                                          (VP (TO:[1407..1409] to)
                                            (VP (VB:[1410..1417] depress)
                                              (NP (NN:[1418..1420] AA)
                                                  (NNS:[1421..1427] levels))))
                                          (CC:[1428..1431] and)
                                          (VP (TO:[1432..1434] to)
                                            (VP (VB:[1435..1443] suppress)
                                              (NP
                                                (ADJP (NN:[1445..1446] T)
                                                      (HYPH:[1446..1447] -)
                                                      (VBN:[1447..1456] activated))
                                                (JJ:[1457..1467] copulatory)
                                                 (NN:[1468..1476] behavior)))))))))))))))))))))))
    (.:[1476..1477] .)))

;sentence 10 Span:1478..1593
;T increased the number of ARO-ir cells in POA,  bed nucleus striae terminalis
;(BNST) and tuberal hypothalamus (Tu).
;[1478..1479]:substance:"T"
(SENT
  (S
    (NP-SBJ (NN:[1478..1479] T))
    (VP (VBD:[1480..1489] increased)
      (NP
        (NP
          (NP (DT:[1490..1493] the) (NN:[1494..1500] number))
          (PP (IN:[1501..1503] of)
            (NP (NN:[1504..1510] ARO-ir) (NNS:[1511..1516] cells))))
        (PP-LOC (IN:[1517..1519] in)
          (NP
            (NP (NN:[1520..1523] POA))
            (,:[1523..1524] ,)
            (NP
              (NP
                (NML (NN:[1526..1529] bed) (NN:[1530..1537] nucleus))
                (NN:[1538..1544] striae) (NN:[1545..1555] terminalis))
              (NP (-LRB-:[1556..1557] -LRB-) (NN:[1557..1561] BNST)
                  (-RRB-:[1561..1562] -RRB-)))
            (CC:[1563..1566] and)
            (NP
              (NP (JJ:[1567..1574] tuberal) (NN:[1575..1587] hypothalamus))
              (NP (-LRB-:[1588..1589] -LRB-) (NN:[1589..1591] Tu)
                  (-RRB-:[1591..1592] -RRB-)))))))
    (.:[1592..1593] .)))

;sentence 11 Span:1594..1861
;The T effect  was inhibited by concurrent treatment with aromatase inhibitor
;in Tu, but not in  POA and BNST. This differential effect of the aromatase
;inhibitor fits in very  well with our previous studies of the co-localization
;of aromatase and estrogen  receptors.
;[1598..1599]:substance:"T"
;[1651..1660]:cyp450:"aromatase"
;[1661..1670]:substance:"inhibitor"
;[1736..1745]:cyp450:"aromatase"
;[1746..1755]:substance:"inhibitor"
;[1827..1836]...[1851..1860]:substance:"aromatase"..."receptors"
;[1841..1860]:substance:"estrogen  receptors"
(SENT
  (S
    (NP-SBJ-2 (DT:[1594..1597] The) (NN:[1598..1599] T) (NN:[1600..1606] effect))
    (VP (VBD:[1608..1611] was)
      (VP
        (VP (VBN:[1612..1621] inhibited)
          (NP-2 (-NONE-:[1621..1621] *))
          (PP (IN:[1622..1624] by)
            (NP-LGS
              (NP (JJ:[1625..1635] concurrent) (NN:[1636..1645] treatment))
              (PP (IN:[1646..1650] with)
                (NP (NN:[1651..1660] aromatase) (NN:[1661..1670] inhibitor)))
              (PP-LOC=3 (IN:[1671..1673] in)
                (NP (NN:[1674..1676] Tu))))))
        (,:[1676..1677] ,)
        (CONJP (CC:[1678..1681] but) (RB:[1682..1685] not))
        (VP
          (PP-LOC=3 (IN:[1686..1688] in)
            (NP (NN:[1690..1693] POA) (CC:[1694..1697] and)
                (NN:[1698..1702] BNST))))))
    (.:[1702..1703] .))
  (S
    (NP-SBJ
      (NP (DT:[1704..1708] This) (JJ:[1709..1721] differential)
          (NN:[1722..1728] effect))
      (PP (IN:[1729..1731] of)
        (NP (DT:[1732..1735] the) (NN:[1736..1745] aromatase)
            (NN:[1746..1755] inhibitor))))
    (VP (VBZ:[1756..1760] fits)
      (PRT (IN:[1761..1763] in))
      (ADVP (RB:[1764..1768] very) (RB:[1770..1774] well))
      (PP-CLR (IN:[1775..1779] with)
        (NP
          (NP (PRP$:[1780..1783] our) (JJ:[1784..1792] previous)
              (NNS:[1793..1800] studies))
          (PP (IN:[1801..1803] of)
            (NP
              (NP (DT:[1804..1807] the) (AFX:[1808..1810] co)
                  (HYPH:[1810..1811] -) (NN:[1811..1823] localization))
              (PP (IN:[1824..1826] of)
                (NP
                  (NP (NN:[1827..1836] aromatase)
                    (NML-1 (-NONE-:[1836..1836] *P*)))
                  (CC:[1837..1840] and)
                  (NP (NN:[1841..1849] estrogen)
                    (NML-1 (NNS:[1851..1860] receptors))))))))))
    (.:[1860..1861] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1594..1861]::S:S:

;sentence 12 Span:1862..2085
;The T effect was blocked by R76713 in areas where ARO-ir and estrogen 
;receptor-ir are generally co-localized (Tu) and was not affected in areas
;with  mainly ARO-ir positive, estrogen receptor-ir negative cells (POA,
;BNST).
;[1866..1867]:substance:"T"
;[1890..1896]:substance:"R76713"
;[1923..1941]:substance:"estrogen  receptor"
;[2037..2054]:substance:"estrogen receptor"
(SENT
  (S
    (NP-SBJ-2 (DT:[1862..1865] The) (NN:[1866..1867] T) (NN:[1868..1874] effect))
    (VP
      (VP (VBD:[1875..1878] was)
        (VP (VBN:[1879..1886] blocked)
          (NP-2 (-NONE-:[1886..1886] *))
          (PP (IN:[1887..1889] by)
            (NP-LGS (NN:[1890..1896] R76713)))
          (PP-LOC (IN:[1897..1899] in)
            (NP
              (NP (NNS:[1900..1905] areas))
              (SBAR
                (WHADVP-3 (WRB:[1906..1911] where))
                (S
                  (NP-SBJ
                    (NP (NN:[1912..1918] ARO-ir))
                    (CC:[1919..1922] and)
                    (NP
                      (NML (NN:[1923..1931] estrogen) (NN:[1933..1941] receptor))
                      (HYPH:[1941..1942] -) (NN:[1942..1944] ir)))
                  (VP (VBP:[1945..1948] are)
                    (ADVP (RB:[1949..1958] generally))
                    (ADJP-PRD (AFX:[1959..1961] co) (HYPH:[1961..1962] -)
                              (NN:[1962..1971] localized))
                    (ADVP-3 (-NONE-:[1971..1971] *T*)))))
              (NP (-LRB-:[1972..1973] -LRB-) (NN:[1973..1975] Tu)
                  (-RRB-:[1975..1976] -RRB-))))))
      (CC:[1977..1980] and)
      (VP (VBD:[1981..1984] was) (RB:[1985..1988] not)
        (VP (VBN:[1989..1997] affected)
          (NP-2 (-NONE-:[1997..1997] *))
          (PP-LOC (IN:[1998..2000] in)
            (NP
              (NP (NNS:[2001..2006] areas))
              (PP (IN:[2007..2011] with)
                (NP
                  (ADJP
                    (ADJP (RB:[2013..2019] mainly) (NN:[2020..2026] ARO-ir)
                          (JJ:[2027..2035] positive))
                    (,:[2035..2036] ,)
                    (ADJP
                      (NML
                        (NML (NN:[2037..2045] estrogen)
                             (NN:[2046..2054] receptor))
                        (HYPH:[2054..2055] -) (NN:[2055..2057] ir))
                      (JJ:[2058..2066] negative)))
                  (NNS:[2067..2072] cells)))
              (PRN (-LRB-:[2073..2074] -LRB-)
                (NP (NN:[2074..2077] POA) (,:[2077..2078] ,)
                    (NN:[2079..2083] BNST))
                (-RRB-:[2083..2084] -RRB-)))))))
    (.:[2084..2085] .)))

;sentence 13 Span:2086..2292
;This  suggests anatomical differences in the expression or clearance of
;aromatase  which may be differentially sensitive to androgens and estrogens
;and dependent  upon the presence of sex steroid receptors.
;[2158..2167]:cyp450:"aromatase"
;[2210..2219]:substance:"androgens"
;[2224..2233]:substance:"estrogens"
;[2274..2291]:substance:"steroid receptors"
(SENT
  (S
    (NP-SBJ (DT:[2086..2090] This))
    (VP (VBZ:[2092..2100] suggests)
      (NP (JJ:[2101..2111] anatomical) (NNS:[2112..2123] differences))
      (PP (IN:[2124..2126] in)
        (NP
          (NP
            (NP (DT:[2127..2130] the) (NN:[2131..2141] expression)
                (CC:[2142..2144] or) (NN:[2145..2154] clearance))
            (PP (IN:[2155..2157] of)
              (NP (NN:[2158..2167] aromatase))))
          (SBAR
            (WHNP-1 (WDT:[2169..2174] which))
            (S
              (NP-SBJ-1 (-NONE-:[2174..2174] *T*))
              (VP (MD:[2175..2178] may)
                (VP (VB:[2179..2181] be)
                  (ADJP-PRD
                    (ADJP
                      (ADVP (RB:[2182..2196] differentially))
                      (JJ:[2197..2206] sensitive)
                      (PP (TO:[2207..2209] to)
                        (NP (NNS:[2210..2219] androgens) (CC:[2220..2223] and)
                            (NNS:[2224..2233] estrogens))))
                    (CC:[2234..2237] and)
                    (ADJP (JJ:[2238..2247] dependent)
                      (PP (IN:[2249..2253] upon)
                        (NP
                          (NP (DT:[2254..2257] the) (NN:[2258..2266] presence))
                          (PP (IN:[2267..2269] of)
                            (NP
                              (NML (NN:[2270..2273] sex)
                                   (NN:[2274..2281] steroid))
                              (NN:[2282..2291] receptors))))))))))))))
    (.:[2291..2292] .)))

;section 14 Span:2296..2339
;PMID: 1638401 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[2296..2300] PMID) (::[2300..2301] :) (CD:[2302..2309] 1638401)
        (-LRB-:[2310..2311] -LSB-) (NNP:[2311..2317] PubMed) (::[2318..2319] -)
        (NN:[2320..2327] indexed) (IN:[2328..2331] for)
        (NNP:[2332..2339] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[2339..EOF] ]

(ORPH -RSB-)
